作者: Tachkov, Konstantin ; McTaggart, Stuart ; Selke, Gisbert ; Bonanno, Patricia Vella ; Garuolienė, Kristina ; Laius, Ott ; Langner, Irene ; Nachtnebel, Anna ; Hoffmann, Mikael ; Fürst, Jurij ; Petrova, Guenka ; Zara, Corinne ; Pontes, Caridad ; Hinteregger, Manfred ; Rutkowski, Jakub ; Krulichová, Iva Selke ; Godman, Brian ; Henkuzens, Svens ; Hoxha, Iris ; Tubic, Biljana ; Jakupi, Arianit ; Allocati, Eleonora ; Kurdi, Amanj ; Jakovljevic, Mihajlo ; Mardare, Ileana ; Pedrola, Marta Turu ; Gulbinovič, Jolanta ; Pisana, Alice ; Banzi, Rita ; Nejezchlebova, Radka ; Inotai, András ; Marković-Peković, Vanda ; Holmes, Carol ; Campbell, Stephen ; Wladysiuk, Magdalene ; Slabý, Juraj ; Kalemeera, Francis ; Ingeberg, Skule ; Sauermann, Robert ; MacBride-Stewart, Sean ; Harsanyi, András ; Wettermark, Bjorn ; Kourafalos, Vasileios ; Melien, Øyvind

[This corrects the article DOI: 10.1155/2021/9996193.].

2021-06-03·Acta Oncologica2区 · 医学

Nestin and CD34 expression in colorectal cancer predicts improved overall survival

2区 · 医学

Article

作者: Tornillo, Luigi ; Felekouras, Evangelos ; Spagnoli, Giulio C. ; Delko, Tarik ; Kancherla, Venkatesh ; Tampakis, Athanasios ; Piscuoglio, Salvatore ; Droeser, Raoul A. ; von Holzen, Urs ; von Flüe, Markus ; Weixler, Benjamin ; Rast, Silvan ; Tampaki, Ekaterini-Christina ; Kettelhack, Christoph ; Ng, Charlotte K. Y. ; Nikiteas, Nikolaos ; Soysal, Savas D. ; Cremonesi, Eleonora ; Bolli, Martin ; Däster, Silvio ; Tosti, Nadia ; Terracciano, Luigi ; Eppenberger-Castori, Serenella

BACKGROUNDNestin, a class VI intermediate filament protein of the cytoskeleton, and CD34, a transmembrane phosphoglycoprotein, are markers of progenitor cells. This study aimed to evaluate their expression and clinical significance in colorectal cancer.METHODSA clinically annotated tissue microarray, including 599 patients with colorectal cancer, was analyzed by immunohistochemistry. Furthermore, nestin and CD34 correlations with HIF-1a and a panel of cytokines and chemokines were assessed using quantitative reverse transcription PCR and The Cancer Genome Atlas dataset.RESULTSExpression of nestin and CD34 was observed only in the tumor stroma. Patients displaying high expression of nestin and CD34 demonstrated higher rates of T1 and T2 tumors (p = .020), lower vascular invasion (p < .001) and improved 5-year overall survival (65%; 95% CI = 55-73 vs 45%; 95% CI = 37-53) after adjusting for clinicopathological characteristics (HR: 0.67; 95% CI = 0.46-0.96). A moderate to strong correlation (r = 0.37-0.78, p < .03) of nestin and CD34 was demonstrated for the following markers; HIF-1α, CD4, CD8, FOXP3, IRF1, GATA3, CCL2, CCL3, CXCL12 and CCL21.CONCLUSIONSCombined expression of nestin and CD34 expression is associated with better overall survival possibly by modulating a favorable immune response.

2021-01-01·BioMed Research International3区 · 生物学

Utilisation Trend of Long‐Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications

3区 · 生物学

ArticleOA

作者: Nejezchlebova, Radka ; Pedrola, Marta Turu ; McTaggart, Stuart ; Campbell, Stephen ; Hoxha, Iris ; Mardare, Ileana ; Holmes, Carol ; Sauermann, Robert ; Pontes, Caridad ; Harsanyi, András ; Tubic, Biljana ; Ingeberg, Skule ; Melien, Øyvind ; Bonanno, Patricia Vella ; Slabý, Juraj ; Zara, Corinne ; Gulbinovič, Jolanta ; Kourafalos, Vasileios ; Marković-Peković, Vanda ; Garuolienė, Kristina ; Rutkowski, Jakub ; Godman, Brian ; Petrova, Guenka ; Hinteregger, Manfred ; Wettermark, Bjorn ; Krulichová, Iva Selke ; Allocati, Eleonora ; Kurdi, Amanj ; Nachtnebel, Anna ; Tachkov, Konstantin ; Jakovljevic, Mihajlo ; Banzi, Rita ; Kalemeera, Francis ; Wladysiuk, Magdalene ; Fürst, Jurij ; Laius, Ott ; Langner, Irene ; MacBride-Stewart, Sean ; Jakupi, Arianit ; Henkuzens, Svens ; Pisana, Alice ; Inotai, András ; Hoffmann, Mikael ; Selke, Gisbert

Background. Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with long‐acting insulin analogues developed to reduce hypoglycaemia and improve patient convenience. There are concerns though with their considerably higher costs, but moderated by reductions in complications and associated costs. Biosimilars can help further reduce costs. However, to date, price reductions for biosimilar insulin glargine appear limited. In addition, the originator company has switched promotional efforts to more concentrated patented formulations to reduce the impact of biosimilars. There are also concerns with different devices between the manufacturers. As a result, there is a need to assess current utilisation rates for insulins, especially long‐acting insulin analogues and biosimilars, and the rationale for patterns seen, among multiple European countries to provide future direction. Methodology. Health authority databases are examined to assess utilisation and expenditure patterns for insulins, including biosimilar insulin glargine. Explanations for patterns seen were provided by senior‐level personnel. Results. Typically increasing use of long‐acting insulin analogues across Europe including both Western and Central and Eastern European countries reflects perceived patient benefits despite higher prices. However, activities by the originator company to switch patients to more concentrated insulin glargine coupled with lowering prices towards biosimilars have limited biosimilar uptake, with biosimilars not currently launched in a minority of European countries. A number of activities were identified to address this. Enhancing the attractiveness of the biosimilar insulin market is essential to encourage other biosimilar manufacturers to enter the market as more long‐acting insulin analogues lose their patents to benefit all key stakeholder groups. Conclusions. There are concerns with the availability and use of insulin glargine biosimilars among European countries despite lower costs. This can be addressed.

100 项与 National Organization for Healthcare Services Provision 相关的药物交易

登录后查看更多信息

100 项与 National Organization for Healthcare Services Provision 相关的转化医学

登录后查看更多信息